Patents
Sitemap › C12 - Biochemistry; Beer; Spirits; Wine; Vinegar; Microbiology; Enzymology; Mutation or genetic engineering › C12N - Micro-organisms or enzymes; Compositions thereof; Propagating, preserving, or maintaining micro-organisms; Mutation or genetic engineering; Culture media › C12N 5 - Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
Patents for C12N 5 - Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor (182,629)
12/2002
12/12/2002WO2002099088A1 Double-transfected cell line useful for the identification of transport inhibitors
12/12/2002WO2002099087A2 Cell populations for detecting neuronal targets and potential active ingredients
12/12/2002WO2002099083A2 Gfats as modifiers of the p53 pathway and methods of use
12/12/2002WO2002099075A2 Prmts as modifiers of the p53 pathway and methods of use
12/12/2002WO2002099074A2 Slc7s as modifiers of the p53 pathway and methods of use
12/12/2002WO2002099070A2 Compositions and methods for high-level, large-scale production of recombinant proteins
12/12/2002WO2002099069A2 Modulating neuronal outgrowth via the major histocompatibility complex class i (mhc i) molecule
12/12/2002WO2002099068A2 Lces as modifiers of the p53 pathway and methods of use
12/12/2002WO2002099063A2 Alteration of embryo/endosperm size during seed development
12/12/2002WO2002099060A2 Dgks as modifiers of the p53 pathway and methods of use
12/12/2002WO2002099059A2 U5-200KDs AS MODIFIERS OF THE p53 PATHWAY AND METHODS OF USE
12/12/2002WO2002099058A2 KCNMAs AS MODIFIERS OF THE p53 PATHWAY AND METHODS OF USE
12/12/2002WO2002099057A2 Sams modifiers of the p53 pathway and methods of use
12/12/2002WO2002099056A2 C22c7orfs as modifiers of the p53 pathway and methods of use
12/12/2002WO2002099055A2 Cips as modifiers of the p53 pathway and method of use
12/12/2002WO2002099054A2 Hccss as modifiers of the p53 pathway and methods of use
12/12/2002WO2002099053A2 Slc22as as modifiers of the p53 pathway and methods of use
12/12/2002WO2002099052A2 Opns as modifiers of the p53 pathway and methods of use
12/12/2002WO2002099051A2 Nits as modifiers of the p53 pathway and methods of use
12/12/2002WO2002099050A2 Tprs as modifiers of the p53 pathway and methods of use
12/12/2002WO2002099049A2 Tbc1d1s as modifiers of the p53 pathway and methods of use
12/12/2002WO2002099048A2 LIMKs AS MODIFIERS OF THE p53 PATHWAY AND METHODS OF USE
12/12/2002WO2002099047A2 PROMLs AS MODIFIERS OF THE p53 PATHWAY AND METHODS OF USE
12/12/2002WO2002099046A2 Spo11 as modifier of the p53 pathway and methods of use
12/12/2002WO2002099044A2 B3galts as modifiers of the p53 pathway and methods of use
12/12/2002WO2002099042A2 Cads as modifiers of the p53 pathway and methods of use
12/12/2002WO2002099041A2 Ces2s as modifiers of the p53 pathway and methods of use
12/12/2002WO2002099040A2 Igs as modifiers of the p53 pathway and methods of use
12/12/2002WO2002099036A2 Inhibition of neurodegeneration
12/12/2002WO2002099035A2 Chimeric alphavirus replicon particles
12/12/2002WO2002098920A1 Molecules and methods for inhibiting shedding of kim-1
12/12/2002WO2002098916A2 Transcriptional regulator of genes involved in the control of cell growth or cell proliferation. use of said regulator as a therapeutic or diagnostic agent
12/12/2002WO2002098907A2 Cation conducting gabaa receptors and their use
12/12/2002WO2002098899A2 CHDs AS MODIFIERS OF THE p53 PATHWAY AND METHODS OF USE
12/12/2002WO2002098898A2 FLJs AS MODIFIERS OF THE p53 PATHWAY AND METHODS OF USE
12/12/2002WO2002098891A2 GADs AS MODIFIERS OF THE p53 PATHWAY AND METHODS OF USE
12/12/2002WO2002098890A2 MARKs AS MODIFIERS OF THE p53 PATHWAY AND METHODS OF USE
12/12/2002WO2002098889A2 MAP3Ks AS MODIFIER OF THE p53 PATHWAY AND METHODS OF USE
12/12/2002WO2002098474A1 Scaffold product for human bone tissue engineering, methods for its preparation ans uses thereof
12/12/2002WO2002098469A1 In vivo assay for anti angiogenic compounds
12/12/2002WO2002098468A1 SLC13As AS MODIFIERS OF THE p53 PATHWAY AND METHODS OF USE
12/12/2002WO2002098467A1 Slc2as as modifiers of the p53 pathway and methods of use
12/12/2002WO2002098458A1 Sphingosine kinase interacts with traf2 and modulates tumor necrosis factor-induced cellular activity
12/12/2002WO2002098369A2 Mutant forms of cholera holotoxin as an adjuvant
12/12/2002WO2002098368A2 Mutant forms of cholera holotoxin as an adjuvant
12/12/2002WO2002098365A2 Conditioned cell culture media and uses thereof
12/12/2002WO2002098361A2 T cell induced tissue repair and regeneration
12/12/2002WO2002098360A2 Stress protein compositions and methods for prevention and treatment of cancer and infectious disease
12/12/2002WO2002098357A2 Microfabricated tissue as a substrate for pigment epithelium transplantation
12/12/2002WO2002098356A2 Ppp2cs as modifiers of the p53 pathway and methods of use
12/12/2002WO2002098355A2 Methods and reagents for diagnosis and treatment of insulin resistance and related conditions
12/12/2002WO2002098278A2 Peripheral blood fibrocytes differentiation pathway and migration to wound sites
12/12/2002WO2002098217A1 Method for targeting transcriptionally active loci
12/12/2002WO2002085306A3 Use of follistatin to increase muscle mass
12/12/2002WO2002083879A3 Immunotherapy based on dendritic cells
12/12/2002WO2002081751A3 A method of increasing endogenous leptin production
12/12/2002WO2002079239A9 Chimeric filovirus glycoprotein
12/12/2002WO2002077212A3 D-carbamoylase from arthrobacter crystallopoietes dsm 20117
12/12/2002WO2002076206A3 Methods and compositions for cryopreservation of dissociated primary animal cells
12/12/2002WO2002074798A3 The genome of a bifidobacterium
12/12/2002WO2002070552A3 POLYPEPTIDE FROM A HDM2 PROTEIN SPECIFIC MURINE Α/β T-CELL RECEPTORS, NUCLEIC ACIDS CODING FOR THE ABOVE AND USE THEREOF
12/12/2002WO2002064754A3 Medium for culturing tumour cells
12/12/2002WO2002062972A3 Hybridoma cell line g250 and its use for producing monoclonal antibodies
12/12/2002WO2002062967A3 Multipotent o-2a progenitors from the neurohypophysis
12/12/2002WO2002062297A9 Methods and compositions for modulating gluconeogenesis using pgc-1
12/12/2002WO2002061052A3 An improved in vitro method of culturing mammalian cells for autologous cell implantation/transplantation methods
12/12/2002WO2002059612A3 Animal model and cell-line expressing modified chlorine channel
12/12/2002WO2002048322A3 Recombinant porcine liver esterases, their use and a method for the production thereof
12/12/2002WO2002046404A3 Schizophrenia-related voltage-gated ion channel gene and protein
12/12/2002WO2002034891A3 Immortalized preosteoblasts and method for their production
12/12/2002WO2002030958A3 Casein peptide fragments with growth-influencing activity on cell cultures
12/12/2002WO2002026941A3 Primitive neural stem cells and method for differentiation of stem cells to neural cells
12/12/2002WO2002024749A3 Isolated human transporter proteins, nucleic acid molecules encoding them, and uses thereof
12/12/2002WO2002018557A3 Human kinases
12/12/2002WO2002008292A3 Human monoclonal antibody against hepatitis c virus e2 glycoprotein
12/12/2002WO2002002775A3 Calpain protease 12
12/12/2002WO2001093983A9 Secreted and transmembrane polypeptides and nucleic acids encoding the same
12/12/2002WO2001089568A9 Nrg-2 nucleic acid molecules, polypeptides, and diagnostic and therapeutic methods
12/12/2002WO2001038360A9 Novel hcv non-structural polypeptide
12/12/2002WO2001027303A9 Adeno-associated virus vectors encoding factor viii and methods of using the same
12/12/2002WO2000032152A3 Compositions and methods for regulating bacterial pathogenesis
12/12/2002US20020188963 Embryonic stem cells for use in development of treatments for nervous system, cardiovascular and tumor disorders
12/12/2002US20020188961 Non human transgenic animal in which the expression of the gene coding for insulin is deleted
12/12/2002US20020188349 Tissue engineered blood vessels and apparatus for their manufacture
12/12/2002US20020188240 Process and apparatus for utilization of in vivo extracted plasma with tissue engineering devices, bioreactors, artificial organs, and cell therapy applications
12/12/2002US20020188109 Expression vector for use transformation of yeast cells
12/12/2002US20020187992 Prodrugs via acylation with cinnamate
12/12/2002US20020187972 Methods for modulating expression of exogenous genes in mammalian systems
12/12/2002US20020187946 Mammalian iap gene family, primers, probes and detection methods
12/12/2002US20020187936 Methods of treating liver disease and liver damage with growth hormone and foxM1B
12/12/2002US20020187931 Modulating cell survival by modulating huntingtin function
12/12/2002US20020187930 Substances and their uses
12/12/2002US20020187553 Packaging systems for human recombinant adenovirus to be used in gene therapy
12/12/2002US20020187551 Culturing and proliferating isolated Langerhans islets endocrine cells; obtain viable langerhans islets endocrine cells, incubate with cell propagation proteins, recover cells
12/12/2002US20020187550 Generation of genetically engineered cells; obtain embryonic stem cells, culture, incubate with cytokine, recover differentiated cells
12/12/2002US20020187549 Derivation of pluripotential embryonic cell lines from domestic animals
12/12/2002US20020187548 Method for identification of cell growth or differentiation factors
12/12/2002US20020187540 Cloning and characterization of a human adenylyl cyclase
12/12/2002US20020187537 Culture product; polypeptide
12/12/2002US20020187523 Extracellular signaling molecules
1 ... 1268 1269 1270 1271 1272 1273 1274 1275 1276 1277 1278 1279 1280 1281 1282 1283 1284 1285 1286 1287 1288 ... 1827